Lilly Acquires Verve Therapeutics in $1.3B Deal to Pioneer One-Time Gene Editing Therapies for Heart Disease

Indianapolis, IN, June 17, 2025 (PRNewswire) -- Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion to expand into one-time gene editing therapies for cardiovascular disease. Verve’s lead candidate, VERVE-102, aims to transform treatment for ASCVD by offering lifelong benefits from a single dose. The acquisition strengthens Lilly’s cardiometabolic portfolio and accelerates innovation in genetic medicine.

Read full article here.